InnoCom Bio Equities
Fund of fundsSan Francisco · Pre-Seed–Seed · 8 people tracked
Investment thesis
Innocombio structures portfolio investments in early-stage life sciences technologies, providing seed capital and access to innovative intellectual property. The firm emphasizes diversified risk exposure across multiple technologies, synergies among portfolio companies, and alternative monetization pathways including royalties and licensing opportunities for founders seeking to accelerate value creation.
Source: firm website, verified Jul 21, 2026.
Team · 8 people
from the firm's website
Co-founder and CEO of InnoCom Bio with extensive finance and business leadership experience. Previously served as managing director for finance at Esperance Private Equity and held executive roles at multiple organizations including Halo Confections and Metro Pacific Development.
Veterinarian and co-founder of InnoCom Bio with expertise in animal health research and contract research organizations. Founder and CEO of Veterinary Health Research Centers and has held senior roles at leading CROs including Covance, with specialized focus on canine health treatment development.
Veterinary medicine professional and co-founder of InnoCom Bio. Founded Pacific AgVet and serves as proprietor of Pacific AH Consulting, with additional co-founder roles at Kiah Bio, Sprint Health, and Bilby BioPure.
Co-founder of 3I'SVIEW, INC with extensive sales, finance, and consulting experience across multiple Fortune 500 companies. Brings expertise in capital markets and equity specialization from prior roles at Bank of America and other major financial institutions.
Executive director at Phoenix Biotechnology with 28 years of life science experience. Brings expertise from major pharmaceutical companies including Abbott Laboratories and Daiichi Sankyo, with successful product launches and exits in the healthcare space.
CEO and co-founder of Fintegrate Consulting with two decades of management consulting experience focused on international growth. Founder and chairman of the Swiss-American Chamber of Commerce in Southern California, specializing in US-Switzerland business development.
Managing director at Excel Venture Management with extensive venture capital and life sciences expertise. Previously managed a $225M fund invested in over 40 life science companies and served as senior executive or founder at multiple NASDAQ-listed and private companies, with 130+ co-authored scientific publications.
COO and co-founder of Menten AI with advanced bioinformatics expertise. Brings research experience from KTH Royal Institute of Technology and Caltech, and founded a Y Combinator-backed company.
Investments · 11 tracked
founders shown can be your intro pathFast-acting antimicrobial surface technology that eliminates 99.9% of bacteria, fungus, and viruses in under 2 minutes on high-touch surfaces.
MedTech appliance with 43 issued patents enabling comprehensive management of antibiotic-resistant infections and conventional wound care in human and animal health.
Plant-based biopharmaceutical production platform providing cost-effective, scalable biosimilar and biologics manufacturing using proprietary bioengineering technology.
Lung protein replacement therapy addressing deficiencies in respiratory conditions including COVID-19 sequelae, pneumonia, asthma, and COPD in humans and animals.
Repurposed drug therapy targeting orphan indications in Restrictive Cardiomyopathy with reduced regulatory pathway compared to traditional drug development.
Repurposed drug ESNtx005 targeting orphan indications in Restrictive Cardiomyopathy with superior efficacy demonstrated in historical clinical data.
realSKIN® biotherapeutic utilizing genetically engineered, pathogen-free porcine cells for live skin replacement with integrated vasculature, eliminating patient rejection.
Novel herpes virus platform engineered for safety, serving as viral vectors for HSV-1 prophylactic vaccine and HSV-2 therapeutic vaccine with UK fast-track designation.
Biotech company developing transformational drugs targeting aggressive ovarian and esophageal cancers with integrated biomarker identification systems.
Precision medicine platform delivering a first-in-class anti-solid tumor drug with composition patents in 32 countries, targeting both canine and human markets.
Haemoglobin-based oxygen carrier platform addressing severe blood loss and hemorrhagic shock in military, civilian, and veterinary trauma with significant federal contract funding.
Frequently asked questions
- What stage does InnoCom Bio Equities invest at?
- InnoCom Bio Equities invests at the Pre-Seed, Seed stages.
- What sectors does InnoCom Bio Equities focus on?
- InnoCom Bio Equities focuses on Biotech, Digital Health, Healthtech.
- Where is InnoCom Bio Equities located?
- InnoCom Bio Equities is headquartered in San Francisco, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
An AI-first venture capital firm founded in 2016 that invests across the full AI stack, including next-generation compute chips, AI infrastructure, robotics, and agentic AI solutions. The team originated from Stanford and leverages deep domain expertise and access to frontier research talent.
Hyderabad Angels is a collective of experienced entrepreneurs, industrialists, and family offices founded in 2010 that provides mentorship, capital, and network access to early-stage founders. The organization invests in seed and pre-seed companies across sector-agnostic technology, healthcare, consumer, and other emerging sectors.